RSS Feed
- 44% of Homeowners With a Mortgage Can't Sell: Zillow
- Tim Cook Should Tell Congress to Kiss His Ass
- Millennials Won't Be Debt Free Until They Die
- Biotech Stock Mailbag: Amarin, MannKind, Palatin
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
Article
Biotech Stock Mailbag: Amarin, MannKind, Palatin
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
07:00AM 05/24/13
Article
Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE)
Two charts show how investors feel differently about Keryx and Acadia Pharma.
10:38AM 05/21/13
Article
2013 FDA Drug Approval Calendar
An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.
07:00AM 05/21/13
Article
Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
07:00AM 05/17/13
Article
ASCO '13 Preview: Oncothyreon's Failed Lung Cancer Vaccine
Here's why Stimuvax didn't help lung cancer patients live longer.
06:00PM 05/15/13
Article
10 ASCO '13 Abstracts You Can Read Right Now
Get a head start on searching through ASCO abstracts with these 10 summaries.
06:00PM 05/15/13
Article
ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Up
New data suggests Roche's GA101 is more potent than the blockbuster Rituxan.
06:00PM 05/15/13
Article
ASCO '13 Preview: Gilead's Big Cancer Debut
More than half of patients responded to treatment with Gilead's idelalisib in a phase I study.
06:00PM 05/15/13
Article
ASCO '13 Preview: New 'Anti-PD-1' Therapies Shrink Tumors
A new class of immune-boosting drugs are showing great promise against melanoma, lung and kidney cancers.
06:00PM 05/15/13
Article
SEC Is Investigating Spectrum Pharma
Regulators have issued a subpoena to Spectrum for information related to the steep cut in Fusilev sales in 2013.
07:19AM 05/13/13